Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone513-579-9911
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$704.59 million
Profitability
Miscellaneous
Employees2,900
Next Earnings Date7/29/2019 (Estimated)
OptionableOptionable
Medpace (NASDAQ:MEDP) Frequently Asked Questions
What is Medpace's stock symbol?
Medpace trades on the NASDAQ under the ticker symbol "MEDP."
How were Medpace's earnings last quarter?
Medpace Holdings Inc (NASDAQ:MEDP) posted its quarterly earnings data on Monday, April, 29th. The company reported $0.64 EPS for the quarter, beating the Zacks' consensus estimate of $0.60 by $0.04. The firm had revenue of $200.70 million for the quarter, compared to the consensus estimate of $190.16 million. Medpace had a net margin of 10.49% and a return on equity of 17.16%. The firm's revenue was up 23.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.60 EPS. View Medpace's Earnings History.
When is Medpace's next earnings date?
What guidance has Medpace issued on next quarter's earnings?
Medpace issued an update on its FY19 earnings guidance on Monday, April, 29th. The company provided EPS guidance of $2.58-2.69 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.67. The company issued revenue guidance of $813-837 million, compared to the consensus revenue estimate of $794.97 million.Medpace also updated its FY 2019 guidance to $2.58-2.69 EPS.
What price target have analysts set for MEDP?
5 equities research analysts have issued 12-month target prices for Medpace's shares. Their forecasts range from $49.00 to $63.00. On average, they anticipate Medpace's share price to reach $58.00 in the next year. This suggests a possible upside of 1.4% from the stock's current price. View Analyst Price Targets for Medpace.
What is the consensus analysts' recommendation for Medpace?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.
Has Medpace been receiving favorable news coverage?
Media headlines about MEDP stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medpace earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an impact on the company's share price in the next few days.
Who are some of Medpace's key competitors?
Some companies that are related to Medpace include Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Geovax Labs (GOVX), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA) and Senomyx (SNMX).
What other stocks do shareholders of Medpace own?
Who are Medpace's key executives?
Medpace's management team includes the folowing people:
- Dr. August James Troendle, Chairman, Pres & CEO (Age 63)
- Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)
- Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)
- Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)
- Mr. Todd Meyers, VP of Bus. Devel. & Marketing
When did Medpace IPO?
(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.
Who are Medpace's major shareholders?
Medpace's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.54%), Pendal Group Ltd (4.14%), Wasatch Advisors Inc. (3.92%), Acadian Asset Management LLC (3.59%), Voya Investment Management LLC (1.92%) and Dimensional Fund Advisors LP (1.64%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Institutional Ownership Trends for Medpace.
Which major investors are selling Medpace stock?
MEDP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Wells Fargo & Company MN, Federated Investors Inc. PA, Pendal Group Ltd, ClariVest Asset Management LLC, OppenheimerFunds Inc., Acadian Asset Management LLC and Jacobs Levy Equity Management Inc.. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Insider Buying and Selling for Medpace.
Which major investors are buying Medpace stock?
MEDP stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., MERIAN GLOBAL INVESTORS UK Ltd, PNC Financial Services Group Inc., Sio Capital Management LLC, Norris Perne & French LLP MI, Assenagon Asset Management S.A., Dimensional Fund Advisors LP and Dixon Hubard Feinour & Brown Inc. VA. View Insider Buying and Selling for Medpace.
How do I buy shares of Medpace?
Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Medpace's stock price today?
One share of MEDP stock can currently be purchased for approximately $57.21.
How big of a company is Medpace?
Medpace has a market capitalization of $2.05 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,900 workers across the globe.
What is Medpace's official website?
How can I contact Medpace?
Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]
MarketBeat Community Rating for Medpace (NASDAQ MEDP)
MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
